In Italy and worldwide, the availability of different classes of antiretroviral drugs led the achievement
of lasting therapeutic efficacy in most PLWH. However, there is a minority of patients that are resistant to the four antiretroviral classes
used (nucleoside reverse transcriptase inhibitors or NRTIs, non-NRTIs or NNRTIs, protease inhibitors or PIs, and integrase strand transfer inhibitors
or InSTIs), with serious implications both individually and for the community. To date, the treatment of these patients is one of the most important
challenges in the context of HIV infection treatment strategies.
PRESTIGIO aims to improve the management of multi-resistant patients through the creation of a national registry, which collects and shares information
(clinical and laboratory data, blood samples) in order to:
Assess the prognosis, in terms of disease survival and progression, long-term clinical complications and quality of life.
Assess the efficacy and safety of antiretroviral drugs prescribed in these patients.
Evaluate the predictors of virological failure in patients with negative viremia.
Evaluate in patients with positive viremia:
-genotypic and phenotypic susceptibility to new drugs developed ;
-the characteristics useful to favor the optimization of the therapy and to maintain, where the virological suppression
is not achievable, the best virological and immunological profile in order to contrast the progression of the disease.
Finally, the creation of Prestigio aims to promote communication and information on multiresistance, on how to access new drugs and on
new therapeutic strategies in the field of HIV infection.